SBH
FBIO icon

Segall Bryant & Hamill’s Fortress Biotech FBIO Stock Holding History

Segall Bryant & Hamill’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-941
Closed -$23K – 843
2018
Q3 		$23K Hold
941
– – ﹤0.01% 841
2018
Q2 		$42K Buy
+941
New +$53K ﹤0.01% 850

Other funds holding FBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Segall Bryant & Hamill's FBIO Position: Q4 2018 in Review

Segall Bryant & Hamill sold out of Fortress Biotech (FBIO) in Q4 2018, closing a stake of 941 shares — an estimated $23K sold.

Segall Bryant & Hamill first reported a position in FBIO in Q2 2018 and held it in 2 quarters. The position peaked at $42K in Q2 2018. 61 funds tracked by Wall St. Rank hold FBIO as of Q4 2018.

  • Segall Bryant & Hamill reported no remaining Fortress Biotech position as of Q4 2018 after selling out during the quarter.
  • Segall Bryant & Hamill sold 941 Fortress Biotech shares in Q4 2018, an estimated $23K.
  • Segall Bryant & Hamill first reported a position in Fortress Biotech in Q2 2018 and held it in 2 quarters.
  • Segall Bryant & Hamill's Fortress Biotech position peaked at $42K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2018.

Based on Segall Bryant & Hamill's 13F filing for Q4 2018, filed 15 Feb 2019.